Comparison of the efficacy and safety of perioperative immunochemotherapeutic strategies for locally advanced esophageal cancer: a systematic review and network meta-analysis

Comparison of the efficacy and safety of perioperative immunochemotherapeutic strategies for locally advanced esophageal cancer: a systematic review and network meta-analysis

BackgroundThe aim of this network meta-analysis was to clarify the efficacy and safety of different immune checkpoint inhibitors (ICIs) in combination with chemotherapy in the neoadjuvant phase for the treatment of locally advanced esophageal cancer.MethodsWe searched PubMed, EMBASE, Web of Science,...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jiao Zhang, Peixi Zhao, Rui Xu, Le Han, Wenjuan Chen, Yili Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	chemotherapy immunotherapy neoadjuvant therapy esophageal carcinoma meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1478377/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study
by: Na Zhou, et al.
Published: (2024-12-01)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II–IVa esophageal cancer: a network meta-analysis
by: Mingxing Wang, et al.
Published: (2025-01-01)

Recent Advances and Hot Spots of Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Carcinoma
by: Huilai LYU, et al.
Published: (2024-12-01)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
by: Tom van den Ende, et al.
Published: (2023-12-01)

Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma
by: Haibo Cai, et al.
Published: (2024-12-01)

From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy
by: Zhengzhou Qiu, et al.
Published: (2024-12-01)

The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study
by: Ruotong Wang, et al.
Published: (2024-09-01)

Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma
by: Xiaofeng Duan, et al.
Published: (2025-01-01)

Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01)

The efficacy of neoadjuvant immunotherapy in gastric cancer, adenocarcinoma of the esophagogastric junction, and esophageal cancer: a meta-analysis
by: Mengyi Qian, et al.
Published: (2024-11-01)

Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study
by: Jifeng Feng, et al.
Published: (2024-12-01)

Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study
by: Hai Zhang, et al.
Published: (2025-01-01)

The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis
by: Jian-Zhou Tian, et al.
Published: (2025-01-01)

Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis
by: Xingyu Zhou, et al.
Published: (2024-12-01)

Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort
by: Wei-Xiang Qi, et al.
Published: (2025-01-01)

Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids
by: Suya Shen, et al.
Published: (2024-12-01)

A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study
by: Fatih Gürler, et al.
Published: (2024-07-01)

Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report
by: Ying Sun, et al.
Published: (2024-12-01)

Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates
by: Xihao Xie, et al.
Published: (2024-12-01)

CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study
by: Yuting Zheng, et al.
Published: (2024-12-01)

Esophageal squamous cell carcinoma with EP300 mutations displays distinct genetic characteristics relevant to neoadjuvant chemoradiotherapy
by: Yutian Lai, et al.
Published: (2025-01-01)

Identification of key genes to predict response to chemoradiotherapy and prognosis in esophageal squamous cell carcinoma
by: Yingying Cui, et al.
Published: (2024-11-01)

The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study
by: Shalika Bohingamu Mudiyanselage, et al.
Published: (2024-12-01)

Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
by: Linfeng Wang, et al.
Published: (2025-01-01)

Case report: Radical robotic nephroureterectomy after chemotherapy followed by avelumab in a patient with node-positive UTUC
by: Hana Studentova, et al.
Published: (2024-11-01)

CT-based habitat radiomics for predicting treatment response to neoadjuvant chemoimmunotherapy in esophageal cancer patients
by: Weibo Kong, et al.
Published: (2024-12-01)

Identification of biomarkers for tumor regression grade in esophageal squamous cell carcinoma patients after neoadjuvant chemoradiotherapy
by: Zhifu Chen, et al.
Published: (2025-01-01)

Comparison of radiation esophagitis associated with daytime versus evening radiotherapy in patients with esophageal carcinoma
by: Yun Xing, et al.
Published: (2025-01-01)

The intratumoral landscape of T cell receptor repertoire in esophageal squamous cell carcinoma
by: Meng Yang, et al.
Published: (2024-11-01)

Aberrant SNHG expression predicts poor prognosis in esophageal cancer using meta-analysis and bioinformatics analysis
by: Ke Shi, et al.
Published: (2025-02-01)

Comparison of mediastinoscopy and thoracoscope minimally invasive esophagectomy in the treatment of esophageal cancer: a meta-analysis and system review
by: Jincheng Wang, et al.
Published: (2025-01-01)

Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels
by: Fei Yang, et al.
Published: (2025-01-01)

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma
by: Haruhiko Yamazaki, et al.
Published: (2023-02-01)

What is true and what is new in esophageal microbiome in 2024?
by: M. Jauvain, et al.
Published: (2024-10-01)

Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma
by: Xueling Shi, et al.
Published: (2025-12-01)

Multimodality deep learning radiomics predicts pathological response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
by: Yunsong Liu, et al.
Published: (2024-11-01)

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
by: Yuanyuan Shen, et al.
Published: (2024-12-01)

Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study
by: Yonggang Yuan, et al.
Published: (2020-07-01)

Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis
by: Chenglong Wang, et al.
Published: (2024-11-01)

A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer
by: Freshte Foroughi, et al.
Published: (2024-12-01)